Sign in Subscribe

Alex Chompff

Vietnamese Cohort Compares Early- vs Late-Onset CRC Outcomes

Skip to content The CRC Digest Vietnamese Cohort Compares Early- vs Late-Onset CRC Outcomes A retrospective study of 486 patients who underwent curative resection in Vietnam's Mekong Delta compared clinicopathologic features and survival between early-onset and late-onset colorectal cancer. (Arq Bras Cir Dig) This content is informational only

Risk Factors for Early-Onset CRC Reviewed

Skip to content The CRC Digest Risk Factors for Early-Onset CRC Reviewed A clinical review highlights that early-onset CRC (diagnosed before age 50) arises from both nonmodifiable factors (age, family history, race/ethnicity) and modifiable factors (obesity, diet, inactivity, alcohol, tobacco). (Gastrointest Endosc Clin N Am) This content is informational

Nanoparticle Platform Targets Radioresistance in KRAS-Mutant CRC

Skip to content The CRC Digest ◇ RESEARCH Nanoparticle Platform Targets Radioresistance in KRAS-Mutant CRC Researchers developed sulfasalazine-loaded hafnium oxide nanoparticles (HfO2@SAS) to overcome radiotherapy resistance in KRAS-mutant colorectal cancer by targeting the SLC7A11/GPX4 pathway and inducing ferroptosis (a form of cell death). (Biomaterials) This content is informational only

Meta-Analysis Examines Fecal Immunochemical Test Accuracy

Skip to content The CRC Digest ▪ SCREENING Meta-Analysis Examines Fecal Immunochemical Test Accuracy A systematic review and meta-analysis evaluated the diagnostic accuracy of quantitative fecal immunochemical tests (FIT) for colorectal cancer and advanced neoplasm, examining variations in performance by sex, geographic region, study design, FIT platform, and positivity threshold. (Cancer

Blood-Based CRC Screening Tests Show Promise but Have Key Limitations

Skip to content The CRC Digest ▪ SCREENING Blood-Based CRC Screening Tests Show Promise but Have Key Limitations Three blood-based CRC screening tests (Epi proColon, Shield, and the Freenome test) have completed large validation studies, but all show low sensitivity for advanced precancerous lesions, low rates of follow-up colonoscopy after an

Early-Onset Colorectal Cancer Incidence Accelerates Through 2023

Skip to content The CRC Digest ▪ SCREENING Early-Onset Colorectal Cancer Incidence Accelerates Through 2023 SEER data show early-onset CRC incidence accelerated during 2019-2023 with an annual percent change of 8.3%, while incidence among adults 65 and older declined. Black patients more often presented with stage IV disease (33.9%

CRC Research Update — September 03, 2026

Today's colorectal cancer research highlights

HER2-Targeted Zanidatamab Produces Response in KRAS-Mutated Rectal Cancer

Skip to content The CRC Digest HER2-Targeted Zanidatamab Produces Response in KRAS-Mutated Rectal Cancer A case report describes a significant response in a 54-year-old male with HER2-amplified, KRAS G12D-mutated metastatic rectal cancer treated with a zanidatamab-based combination regimen. (Frontiers in Immunology) This content is informational only and does not constitute

Screening Age Thresholds Miss Early-Onset CRC Risk Established in Youth

Skip to content The CRC Digest Screening Age Thresholds Miss Early-Onset CRC Risk Established in Youth A new analysis argues that age-based screening creates a "blind spot" for early-onset colorectal cancer because high-risk states may be established through early-life exposures decades before screening begins at age 45. (Frontiers

Real-World Data on Encorafenib Plus Panitumumab in BRAF V600E Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Real-World Data on Encorafenib Plus Panitumumab in BRAF V600E Metastatic CRC A population-based multicenter study examined real-world outcomes of the targeted therapy combination encorafenib plus panitumumab in patients with BRAF V600E-mutated metastatic colorectal cancer. (Clinical Colorectal Cancer) This content is informational only and